Korean J Dermatol.
2010 Oct;48(10):823-831.
Botulinum Toxin Type A for Facial Wrinkles and Benign Masseter Hypertrophy in Korean Patients
- Affiliations
-
- 1The Korean Academy of Botulinum Toxin Therapy (KABOTT), Seoul, Korea. kimsskin@hanmail.net
- 2Leaders Aesthetic Laser and Cosmetic Surgery Center, Seoul, Korea.
- 3Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 4Kimbelle Catholic Skin Clinic, Seoul, Korea.
- 5Pure Skin Clinic, Seoul, Korea.
- 6Yedam Skin Clinic, Seoul, Korea.
- 7Allforskin, Skin Clinic, Seoul, Korea.
- 8SAS Dermatologic Clinic, Seoul, Korea.
- 9Theme Dermatologic Clinic, Seoul, Korea.
- 10Yonsei Star Skin & Laser Clinic, Seoul, Korea.
- 11Medy-Tox Inc., Seoul, Korea.
- 12OhKim's Skin Clinic, Seoul, Korea.
- 13Best Skin Clinic, Seoul, Korea.
- 14CNP Skin Clinic, Seoul, Korea.
Abstract
- BACKGROUND
The utilization of botulinum toxin has rapidly expanded into various aesthetic applications. Achieving success with the aesthetic use of neurotoxins depends on several factors, including an understanding of the anatomy, the methods of dilution and the injection technique. Any guidelines representing a consensus for aesthetic treatments using botulinum toxin type A (BTA) have not been published in Korea.
OBJECTIVE
We wanted to provide consensus recommendations on the treatment of facial wrinkles and benign masseter hypertrophy using BTA in Korean patients.
METHODS
A panel of experienced Korean dermatologists was convened to develop a clinical consensus. The clinical consensus was comprised of the recommendations of the panel and the guidelines on general issues, such as the reconstitution and handling of the BTA, the procedural considerations, the dosing and injection-site standardizations, and the prevention and treatment of unwanted effects. Specific recommendations were provided according to the area of treatment, including glabellar lines, horizontal forehead lines, lateral periorbital wrinkles and benign masseter hypertrophy.
RESULTS
The recommended final concentration of BTA was 50 units/ml (5 units/0.1 ml) after reconstitution with physiologic saline. For glabellar lines, the members recommend three injection points (a total of 8 units). For forehead wrinkles, the members recommend nine injections in two rows into the frontalis with 1 unit/point. For crow's feet, the members recommend three injections per side (7 units/side) at the lateral part of the orbicularis oculi. For benign masseter hypertrophy, three injections per side (24~30 units/side) were recommended.
CONCLUSION
These consensus recommendations will provide a framework for Korean dermatologists who wish to perform safe and efficacious injection of BTA for facial rejuvenation.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A clinical study on the use of botulinum toxin type a in maxillofacial area
- Introduction of Radiofrequency Reduction of Masseter Muscle and Case Reports
- A CASE REPORT OF TREATMENT OF MASSETERIC HYPERTROPHY WITH BOTULINUM TOXIN
- Application of Botulinum Toxin Injection in Plastic Surgery
- A Clinical Study of Facial Wrinkles Affected by Facial Expression Muscles Treated with Botulinum Toxin(Botox(R))
